Takeda Pharmaceutical said a post hoc study on alogliptin showed no increase in the composite rate of cardiovascular mortality and among high-risk patients with diabetes. The results were published in The Lancet.
Eli Lilly and Daiichi Sankyo have submitted the much-watched drug prasugrel to the FDA. The drug--an oral antiplatelet agent--is poised to take on the blockbuster Plavix.
> The FDA has revealed two new studies that show cancer patients may be more likely to die while using Amgen's blockbuster drugs Aranesp and Epogen (also sold under the brand name Procrit by
Syndexa Pharmaceuticals is joining the herd in the
Hoping to calm worries spark by a recent announcement by the FDA that the diabetes drug Byetta is linked to a higher risk of acute pancreatitis, Novo Nordisk said that there is nothing in its data
DARA BioSciences in Raleigh, NC has licensed in IP and compounds for type 2 diabetes and dyslipidemia from Bayer HealthCare AG. Bayer gets an undisclosed upfront fee along with a schedule of
> Novartis is teaming up with MIT to develop new ways to manufacture drugs. The company will give the university $65 million over 10 years to create a new research program. Report > Galvus, a
A high-profile researcher has issued what is now one of many public challenges to the manner in which the FDA speeds approval of certain drugs. Researcher Dr. Clifford J. Rosen is concerned, in
Metabasis Therapeutics announced a pair of setbacks on Tuesday, saying that Schering-Plough is pulling out of a collaboration to develop a new therapy for hepatitis B and that an experimental
Press Release: BMS Reports on First Phase II Short-Term Study of Dapagliflozin